HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened
Heron Therapeutics, Inc. (HRTX) announced its financial results for the three months ended March 31, 2026 in an earnings press release dated May 11, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed with the SEC on May 11, 2026 under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing: Form 8-K filed May 11, 2026 (Accession No. 0001193125-26-215752).
• Period covered: Three months ended March 31, 2026 (Q1 2026).
• Disclosure: Earnings press release furnished as Exhibit 99.1.
• Administrative: Form 8-K also references the Inline XBRL cover page (Item 9.01).

Why It Matters
The earnings press release provides the company’s latest quarterly results and is the primary source investors will use to assess recent revenue, expenses, cash flow and operational progress. Investors should review the furnished press release (Exhibit 99.1) for specific figures and commentary on drivers of performance, then monitor any subsequent SEC filings or investor materials for additional detail.